[CAS NO. 1858276-04-6] Subasumstat (TAK-981)

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1858276-04-6]

Catalog

SLK-S8829

Brand

Selleck

CAS

1858276-04-6

DESCRIPTION [1858276-04-6]

Overview

MDL	MFCD32062692
Molecular Weight	578.10
Molecular Formula	C25H28ClN5O5S2
SMILES	O=S(OC[C@@H]1[C@@H](O)C[C@H](NC2=NC=NC=C2C(C3=CC([C@@H]4NCCC5=C4C=C(Cl)C=C5)=C(C)S3)=O)C1)(N)=O

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	1.7298 mL	8.6490 mL	17.2980 mL
5 mM	0.3460 mL	1.7298 mL	3.4596 mL
10 mM	0.1730 mL	0.8649 mL	1.7298 mL
50 mM	0.0346 mL	0.1730 mL	0.3460 mL

Description

Subasumstat (TAK-981) is a novel, selective inhibitor of the with potential immune-activating and antineoplastic activities.

Targets

SUMOylation enzymatic cascade ^[1]

In vitro

In both mouse bone-marrow and human peripheral blood mononuclear cell derived dendritic cells (DCs), TAK-981 treatment ex vivo induced markers of activation and maturation including CD40, CD80 and CD86, as well as increased secretion of inflammatory cytokines like IP-10, MCP1, MIP-1α, MIP1β, IFNα and IFNβ.

References

[1] Mithun Khattar, et al. Cancer Res 2019;79(13 Suppl):Abstract nr 3252.
[2] Allison J. Berger, et al. Cancer Res 2019;79(13 Suppl):Abstract nr 3079.